REG - IXICO plc - Notice of 2025 Full Year Results and IMC

IXICOAnnouncement

27/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251127:nRSa1484Ja&default-theme=true

RNS Number : 1484J  IXICO plc  27 November 2025

IXICO plc

("IXICO", the "Company" or the "Group")

 

Notice of 2025 Full Year Results and Investor Presentation

 

 

27 November 2025 IXICO plc (AIM: IXI), a global leader in neuroscience
imaging, using its AI-driven platform to help advance drug development in
neurological disorders, confirms it will issue its Full Year Results for the
year to 30 September 2025 on Tuesday 09 December 2025.

 

Bram Goorden (CEO) and Grant Nash (CFO) will provide a live presentation to
all existing and potential shareholders relating to the Full Year Results and
the Company's progress and ongoing strategy via:

 

The Investor Meet Company platform on 09 December 2025 at 16:30 GMT.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
09:00 GMT on 08 December 2025, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet IXICO
PLC via:

 

https://www.investormeetcompany.com/ixico-plc/register-investor
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.investormeetcompany.com%2Fixico-plc%2Fregister-investor&data=05%7C02%7Cjames.chandler%40ixico.com%7Cfd7b2d98fdf74d5f362108dd8303c4d3%7Cd5a3b5c97a6b4ab9abee3de97e9d4955%7C0%7C0%7C638810774401694753%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=DoWkFpNoX3IapWeeYVz5qD7ikqrU%2Fms5pj7zJgFqfaM%3D&reserved=0)

 

Investors who already follow IXICO PLC on the Investor Meet Company platform
will automatically be invited.

 

A recording of the results presentation will be made available on the Group's
website.

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon the publication of this announcement via the Regulatory
Information Service, this inside information is now considered to be in the
public domain.

 

For further information please contact:

 IXICO plc                                   +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited           +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBFBITMTATBBA



            Copyright 2019 Regulatory News Service, all rights reserved